HSPA13 is reported to be increased in B220+ cells from patients with multiple myeloma or systemic lupus erythematosus, whereas mice with B cell–specific deletion of HSPA13 have a reduction in plasmablasts, plasma cells, and antibody induction (50). This evidence concerns the gene PTPRC and plasma cell myeloma.